CN1585641A - 亚肼基－丙二腈化合物 - Google Patents

亚肼基－丙二腈化合物 Download PDF

Info

Publication number
CN1585641A
CN1585641A CNA028222164A CN02822216A CN1585641A CN 1585641 A CN1585641 A CN 1585641A CN A028222164 A CNA028222164 A CN A028222164A CN 02822216 A CN02822216 A CN 02822216A CN 1585641 A CN1585641 A CN 1585641A
Authority
CN
China
Prior art keywords
phenyl
compound
asthma
disease
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028222164A
Other languages
English (en)
Chinese (zh)
Inventor
H-M·埃根韦莱
M·沃尔夫
N·拜尔
P·舍林
T·埃林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN1585641A publication Critical patent/CN1585641A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
CNA028222164A 2001-11-05 2002-10-10 亚肼基－丙二腈化合物 Pending CN1585641A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01125455 2001-11-05
EP01125455.4 2001-11-05

Publications (1)

Publication Number Publication Date
CN1585641A true CN1585641A (zh) 2005-02-23

Family

ID=8179075

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028222164A Pending CN1585641A (zh) 2001-11-05 2002-10-10 亚肼基－丙二腈化合物

Country Status (19)

Country Link
US (2) US7141572B2 (enExample)
EP (1) EP1441730B1 (enExample)
JP (1) JP5116940B2 (enExample)
KR (1) KR100898894B1 (enExample)
CN (1) CN1585641A (enExample)
AR (1) AR040629A1 (enExample)
AT (1) ATE335486T1 (enExample)
AU (1) AU2002363368B2 (enExample)
BR (1) BR0213683A (enExample)
CA (1) CA2465746C (enExample)
DE (1) DE60213841T2 (enExample)
ES (1) ES2268157T3 (enExample)
HU (1) HUP0401747A3 (enExample)
MX (1) MXPA04004263A (enExample)
MY (1) MY129491A (enExample)
PL (1) PL369738A1 (enExample)
RU (1) RU2302412C2 (enExample)
WO (1) WO2003039548A1 (enExample)
ZA (1) ZA200404387B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA82323C2 (uk) * 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
CA2521056A1 (en) * 2003-03-31 2004-10-14 Daiichi Pharmaceutical Co., Ltd. Hydrazone derivative
PE20060272A1 (es) * 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
AU2006237300B2 (en) * 2005-04-19 2011-10-13 Takeda Gmbh Roflumilast for the treatment of pulmonary hypertension
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
ATE478067T1 (de) 2006-03-31 2010-09-15 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
BR122020021551B1 (pt) 2008-11-15 2021-09-21 Melinta Subsidiary Corp Composição farmacêutica antimicrobiana e seu uso
CN102639700A (zh) 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 通过调节自噬增强基因产物调节自噬的方法
WO2011163231A2 (en) * 2010-06-21 2011-12-29 Theracos, Inc. Combination therapy for the treatment of diabetes
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
MD20150071A2 (ro) 2013-02-19 2016-02-29 Pfizer Inc. Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
JO3516B1 (ar) * 2013-03-06 2020-07-05 Janssen Pharmaceutica Nv مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4
WO2015054359A1 (en) * 2013-10-08 2015-04-16 Ebadi Mark A Methods and compositions for symptomatic reflief of the common cold
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
EA031201B1 (ru) 2014-08-06 2018-11-30 Пфайзер Инк. Соединения имидазопиридазина
EP3268085A4 (en) 2015-03-13 2018-10-31 The Board of Trustees of The Leland Stanford Junior University Ltb4 inhibition to prevent and treat human lymphedema
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8400863D0 (en) * 1984-01-13 1984-02-15 Smith Kline French Lab Chemical compounds
DE19632549A1 (de) 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine
DE19826841A1 (de) * 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazine
DE19850701A1 (de) * 1998-11-04 2000-05-11 Merck Patent Gmbh Benzoylpyridazine
DE19932315A1 (de) * 1999-07-10 2001-01-11 Merck Patent Gmbh Benzoylpyridazine

Also Published As

Publication number Publication date
CA2465746C (en) 2011-09-06
HUP0401747A2 (hu) 2005-01-28
DE60213841D1 (de) 2006-09-21
ES2268157T3 (es) 2007-03-16
MXPA04004263A (es) 2004-07-08
AU2002363368B2 (en) 2007-12-13
KR100898894B1 (ko) 2009-05-21
EP1441730B1 (en) 2006-08-09
WO2003039548A1 (en) 2003-05-15
US20040261190A1 (en) 2004-12-30
JP5116940B2 (ja) 2013-01-09
AU2002363368B9 (en) 2003-05-19
US7544684B2 (en) 2009-06-09
RU2302412C2 (ru) 2007-07-10
JP2005511595A (ja) 2005-04-28
RU2004117171A (ru) 2006-01-10
PL369738A1 (en) 2005-05-02
KR20050035177A (ko) 2005-04-15
CA2465746A1 (en) 2003-05-15
US20060270676A1 (en) 2006-11-30
ATE335486T1 (de) 2006-09-15
EP1441730A1 (en) 2004-08-04
ZA200404387B (en) 2006-02-22
AR040629A1 (es) 2005-04-13
US7141572B2 (en) 2006-11-28
HUP0401747A3 (en) 2005-06-28
BR0213683A (pt) 2004-10-26
MY129491A (en) 2007-04-30
DE60213841T2 (de) 2007-02-15

Similar Documents

Publication Publication Date Title
CN1608067A (zh) 作为磷酸二酯酶vii抑制剂的吡咯并嘧啶化合物
CN1659148A (zh) 芳基肟化合物
CN1659147A (zh) 哒嗪衍生物
US7790723B2 (en) Thiazole derivatives as phosphodiesterase IV inhibitors
CN1578665A (zh) 4型磷酸二脂酶抑制剂及其应用
CN1072220C (zh) 作为神经激肽受体拮抗剂的1－苯甲酰基－2－(吲哚基－3－烷基)－哌嗪衍生物
US7141572B2 (en) Hydrazono-malonitriles
CN1404481A (zh) 用作pde4同功酶选择性抑制剂的烟酰胺苯并稠合的杂环衍生物
CN1489588A (zh) 用作pde4同功酶抑制剂的噻唑基,噁唑基,吡咯基,和咪唑基羧酸酰胺衍生物
CN1582277A (zh) 用作糖原合酶激酶3β抑制剂的酰胺衍生物
CN1732006A (zh) 作为p2x7抑制剂、用于治疗炎性疾病的3－(3,5－二氧代－4,5－二氢－3h－(1,2,4)三嗪－2－基)－苯甲酰胺衍生物
CN1291979A (zh) 新的哒嗪衍生物以及含有其作为有效成分的药物
CN1694889A (zh) 用于调节lgE和抑制细胞增殖的苯基－氮杂－苯并咪唑化合物
CN1227547A (zh) 芳基链烷酰基哒嗪
CN1168720C (zh) 芳基链烷酰基哒嗪化合物
AU2002363368A1 (en) Hydrazono-malonitriles
CN1040435C (zh) 联苯基吡啶酮及其制备方法以及它们在药物中的用途
CN1483026A (zh) 苯甲酰哒嗪
HK1070271A (en) Hydrazono-malonitriles
CN1531529A (zh) 用于治疗心脏病和过敏症、具有抑制pde iv作用和 t n f拮抗作用的4－(亚苄基氨基)－3－(甲基硫基)－4h－1，2，4－三嗪－5－酮衍生物
CN1662529A (zh) 作为磷酸二酯酶iv抑制剂的噻唑衍生物
HK1074623A (en) Amide derivatives as glycogen synthase kinase 3-beta inhibitors
HK1050365A (en) Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
HK1060574A (en) Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
HK1063786A (en) Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1070271

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1070271

Country of ref document: HK